8 results
Is addition of a DPP4-inhibitor (vildagliptin) beneficial in type 2 diabetic patients, starting on once daily long-acting insulin in combination with 2 dd metformin. Primary end point is necessary dose of insulin to remain glycemic control.…
To optimize glycemic control in acute ischemic stroke patients.
Primary:To estimate the treatment effects of vildagliptin 50 mg PO BID on 24h weighted-mean glucose (WMG), using CGM and plasma glucose, collected at the end of a two-week treatment period.Secondary:1) To estimate the treatment effects of…
Primary Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.Secondary Objective(s):-To determine the effect of vildagliptin on plasma…
Our primary objective is to study the effect of perioperative intravenous supplementation of omega-3 fatty acids on the perioperative inflammatory response compared to a saline control in patients undergoing surgery for colon cancer.
PrimaryThe 3 months* effect of Vildagliptin on insulin synthesis and storage capacitySecondaryThe 3 months* effect of vildagliptin on- Glucose, insulin, C-peptide levels- Hormonal axes, most importantly GLP1 and GIP and Glucagon- Body weight, body…
The PLANCTON trial will investigate the effect of early intravenous OM-3 FAs on new onset organ failure and mortality in patients with predicted SAP.
The purpose of this study is to determine the safety and efficacy of Nilotinib and Vildagliptin as combination therapy in optimal dosage. In addition, it is investigated whether the addition of Vildagliptin to Nilotinib treatment causes the…